| Description |
EoI No. ICMR/EoI/VU/16/2024/ECD Dated: 01st May, 2024
Expression of Interest (EoI)
For
Transfer of Technology of Human Anti-Measles IgM ELISA assay for
detection of Anti-Measles IgM antibodies in human serum
By ICMR-Hqrs
Indian Council of Medical Research
(Department of Health Research, GoI)
V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar,
New Delhi - 110029, India
1 | 17 P a g e
CONTENTS
Sl. No Section Page No.
1 Letter of Invitation 2
2 Background 3
3 Objective 3
4 Broad Scope of Work 3-4
5 Intellectual Property Rights 5
6 Revenue upon technology rights/Royalty payouts 5-6
7 Publication 6
8 Data Rights 6
9 Details of documents to be furnished 6-7
10 Rejection Criteria 7
11 Evaluation Methodology 7
12 Pre-Qualification Criteria (PQC) 7-9
13 Disclaimer 9
14 Arbitration 9
15 Contacts for enquiry 9
16 Expression of Interest (Format – 1) 10-11
17 Authorization Letter (Format – 2) 12
18 Undertaking with regard to Blacklisting (Format-3) 13
19 Undertaking with regard to Non-Litigation (Format – 4) 14
20 Undertaking with regard to laboratory facility (Format-5) 15
21 Undertaking with regard to production capacity (Format-6) 16
22 SCHEDULE – A (About the Technology) 17
2 | 17 P a g e
Letter of Invitation
1. Invitation of expression of interest
Indian Council of Medical Research (ICMR), New Delhi, invites Expression of Interest (EoI) in hard copy in
a sealed envelope from experienced Indian agencies for undertaking ‘Transfer of Technology of Human
Anti-Measles IgM ELISA assay for detection of Anti-Measles IgM antibodies in human serum” to
be undertaken in two phases.
Phase I: Independent validation of technology “Human Anti-Measles IgM ELISA assay” developed at
ICMR-NIV, Pune after signing a non-disclosure agreement (NDA).
Phase II: Manufacture the above “Human Anti-Measles IgM ELISA assay for detection of AntiMeasles IgM antibodies in human serum” for commercialization if the Phase I experiment is successful.
The EoI Document containing the details of qualification criteria, submission details, brief objective& Scope
of work and evaluation criteria etc. can be downloaded from the ICMR website (https://www.icmr.gov.in)
Schedule for the Proponents is as under:
EOI Document Number ICMR/EoI/VU/16/2024/ECD
Date of Publication 1
st May, 2024
Last date/Time of submission 31st May, 2024
Note:
Interested applicants may please send their proposals in a sealed envelope to the following address:
Head, Division of Communicable Diseases
2
nd Floor, Room No. 303
Indian Council of Medical Research,
V. Ramalingaswami Bhawan,
P.O. Box No. 4911,
Ansari Nagar, New Delhi - 110029, India.
EoI Document No. “ICMR/EoI/VU/16/2024/ECD” along with the title of the EOI as “EoI for
Technology Transfer” in Bold and complete address as above must be clearly mentioned on the
sealed envelope. Only shortlisted firm(s)/organization(s) will be invited to participate in the Request
for Proposal (RFP).
ICMR reserves the right to cancel this EoI and/ or invite afresh with or without amendments, without
liability or any obligation for such EoI and without assigning any reason. Information provided at this
3 | 17 P a g e
stage is indicative and ICMR reserves the right to amend/add any further details in the EoI, as may be
desired by the Competent Authority ICMR and duly notified on its website.
2. Background
The Indian Council of Medical Research (ICMR), New Delhi, the apex body in India for the formulation,
coordination and promotion of biomedical research, is one of the oldest medical research bodies in the world.
The ICMR has always attempted to address itself to the growing demands of scientific advances in biomedical
research on the one hand and to the need of finding practical solutions to the health problems of the country,
on the other.
ICMR- National Institute of Virology (ICMR-NIV), Pune, one of the constituent Institutes of the
Indian Council of Medical Research (ICMR), New Delhi has developed a technology entitled
“Human Anti-Measles IgM ELISA assay for detection of Anti-Measles IgM antibodies in human
serum (hereinafter) referred to as “Technology”.
ICMR is lawfully entitled to enter into any form of non-exclusive agreements with experienced
manufacturing companies hereinafter referred to as the “Company”/ “licensee” through a defined agreement
for Licensing/Commercialization of Human Anti-Measles IgM ELISA assay, hereinafter referred to as
the ‘Product’ which shall be governed by ICMR IP Policy, as revised and approved by the Competent
Authority.
3. Objective
To undertake transfer of Technology of Human Anti-Measles IgM ELISA assay for detection of AntiMeasles IgM antibodies in human, in two phases:
i. To sign a non-disclosure agreement with “Company”/ “licensee” for independent validation of the
‘Technology’ as above.
ii. To manufacture the ‘product’ as above and license it for commercialization and marketing activities.
4. Scope of Work
i. ICMR is willing to collaborate with eligible organizations/companies/ manufacturers for transfer of
Technology of Human Anti-Measles IgM ELISA assay for detection of Anti-Measles IgM antibodies
in human serum in two phases:
Phase I: Independent validation of the Human Anti-Measles IgM ELISA assay after signing a nondisclosure agreement (NDA).
Phase II: Manufacture the Human Anti-Measles IgM ELISA assay for commercialization, if the Phase I
experiment is successful.
ii. The Company would be granted rights to undertake third party validation, further development,
4 | 17 P a g e
manufacture, regulatory approvals, and commercialize the Human Anti-Measles IgM ELISA
assay.
iii. A |